Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

688 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives.
Alves F, Bilbe G, Blesson S, Goyal V, Monnerat S, Mowbray C, Muthoni Ouattara G, Pécoul B, Rijal S, Rode J, Solomos A, Strub-Wourgaft N, Wasunna M, Wells S, Zijlstra EE, Arana B, Alvar J. Alves F, et al. Among authors: goyal v. Clin Microbiol Rev. 2018 Aug 29;31(4):e00048-18. doi: 10.1128/CMR.00048-18. Print 2018 Oct. Clin Microbiol Rev. 2018. PMID: 30158301 Free PMC article. Review.
Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
Rahman R, Goyal V, Haque R, Jamil K, Faiz A, Samad R, Ellis S, Balasegaram M, Boer MD, Rijal S, Strub-Wourgaft N, Alves F, Alvar J, Sharma B. Rahman R, et al. Among authors: goyal v. PLoS Negl Trop Dis. 2017 May 30;11(5):e0005635. doi: 10.1371/journal.pntd.0005635. eCollection 2017 May. PLoS Negl Trop Dis. 2017. PMID: 28558062 Free PMC article. Clinical Trial.
Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India.
Goyal V, Mahajan R, Pandey K, Singh SN, Singh RS, Strub-Wourgaft N, Alves F, Rabi Das VN, Topno RK, Sharma B, Balasegaram M, Bern C, Hightower A, Rijal S, Ellis S, Sunyoto T, Burza S, Lima N, Das P, Alvar J. Goyal V, et al. PLoS Negl Trop Dis. 2018 Oct 22;12(10):e0006830. doi: 10.1371/journal.pntd.0006830. eCollection 2018 Oct. PLoS Negl Trop Dis. 2018. PMID: 30346949 Free PMC article. Clinical Trial.
Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, India.
Goyal V, Burza S, Pandey K, Singh SN, Singh RS, Strub-Wourgaft N, Das VNR, Bern C, Hightower A, Rijal S, Sunyoto T, Alves F, Lima N, Das P, Alvar J. Goyal V, et al. PLoS Negl Trop Dis. 2019 Sep 26;13(9):e0007726. doi: 10.1371/journal.pntd.0007726. eCollection 2019 Sep. PLoS Negl Trop Dis. 2019. PMID: 31557162 Free PMC article.
Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India.
Goyal V, Das VNR, Singh SN, Singh RS, Pandey K, Verma N, Hightower A, Rijal S, Das P, Alvar J, Bern C, Alves F. Goyal V, et al. PLoS Negl Trop Dis. 2020 Jul 20;14(7):e0008429. doi: 10.1371/journal.pntd.0008429. eCollection 2020 Jul. PLoS Negl Trop Dis. 2020. PMID: 32687498 Free PMC article. Clinical Trial.
AmBisome Monotherapy and Combination AmBisome-Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial.
Burza S, Mahajan R, Kazmi S, Alexander N, Kumar D, Kumar V, Lasry E, Harshana A, de Lima Pereira A, Das P, Verma N, Das VNR, Lal CS, Rewari B, Goyal V, Rijal S, Alves F, Gill N, Pandey K. Burza S, et al. Among authors: goyal v. Clin Infect Dis. 2022 Oct 12;75(8):1423-1432. doi: 10.1093/cid/ciac127. Clin Infect Dis. 2022. PMID: 35147680 Free PMC article. Clinical Trial.
Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial.
Andrieux-Meyer I, Tan SS, Thanprasertsuk S, Salvadori N, Menétrey C, Simon F, Cressey TR, Said HRHM, Hassan MRA, Omar H, Tee HP, Chan WK, Kumar S, Thongsawat S, Thetket K, Avihingsanon A, Khemnark S, Yerly S, Ngo-Giang-Huong N, Siva S, Swanson A, Goyal V, Bompart F, Pécoul B, Murad S. Andrieux-Meyer I, et al. Among authors: goyal v. Lancet Gastroenterol Hepatol. 2021 Jun;6(6):448-458. doi: 10.1016/S2468-1253(21)00031-5. Epub 2021 Apr 16. Lancet Gastroenterol Hepatol. 2021. PMID: 33865507 Free PMC article. Clinical Trial.
Bioavailability of three novel oral, sustained-release pellets, relative to an immediate-release tablet containing 500 mg flucytosine: A randomized, open-label, crossover study in healthy volunteers.
Goyal V, Krantz E, Simon F, Neven A, Eriksson J, Saayman A, Ibnou Zekri Lassout N, Louis M, Robinson S, Deshmukh A, Antarkar A, Ruffell C, Victor S, Chenel M, Celebic A, Caplain H, Gillon JY, Ribeiro I. Goyal V, et al. Clin Transl Sci. 2024 Mar;17(3):e13756. doi: 10.1111/cts.13756. Clin Transl Sci. 2024. PMID: 38488418 Free PMC article. Clinical Trial.
Tuberculosis and biologics in rheumatology: A special situation.
Handa R, Upadhyaya S, Kapoor S, Jois R, Pandey BD, Bhatnagar AK, Khanna A, Goyal V, Kumar K. Handa R, et al. Among authors: goyal v. Int J Rheum Dis. 2017 Oct;20(10):1313-1325. doi: 10.1111/1756-185X.13129. Epub 2017 Jul 21. Int J Rheum Dis. 2017. PMID: 28730751 Review.
688 results